Brennan Daniel J.

BSX CFO Brennan sells 84,863 shares at $105.10 avg for $8.9M, trimming 27.3% of holdings; stock near 52-week high.

Brennan Daniel J., EVP and CFO of Boston Scientific, executed 3 separate sales totaling 84,863 shares for $8,919,295.52 between 2025-02-18 and 2025-02-19, reducing his holdings from 310,671 to 225,808 shares. The blended average price of $105.10 is 0.5% below the current price of $105.67 and near the 52-week high of $106.18, placing the execution at an elevated valuation. Against his same-ticker history at BSX, 0 of his 3 prior measurable 90-day outcomes were well-timed (post-sale declines), suggesting a pattern of selling into strength rather than before corrections. The company trades at a P/E of 76.57 on $4.2B in quarterly revenue and +17.6% annual growth, indicating the market has priced in significant future expansion; this high valuation may constrain upside and increase sensitivity to execution shortfalls.

CFO Brennan Daniel J. sold 15,087 shares of BSX at $105.07 for $1.6M on 2025-02-12, retaining 241.5K shares.

Brennan Daniel J., EVP and CFO of Boston Scientific, sold 15,087 shares on 2025-02-12 at $105.07, reducing holdings by 5.9% from 256.5K to 241.5K shares. The sale occurred near the 52-week high of $106.18 and follows a strong 30-day gain of +11.0% and 90-day gain of +22.0% in the stock price. His prior trades at BSX show a pattern of selling into strength—his 2025-01-03 sale posted a 30-day return of +13.9%, and his three measurable same-ticker sales from 2024 all generated positive returns (ranging from +2.4% to +14.4% at the 90-day mark), indicating he has not historically timed these sales to precede declines. The sale represents an opportunistic liquidation at elevated valuation levels (P/E 87.72, stock trading within 0.0% of its 52-week high), consistent with his prior pattern of selling into momentum rather than ahead of weakness.

BSX CFO Brennan sells 9,689 shares at $89.86; holds 223,921 shares post-sale

Brennan Daniel J., EVP and CFO of Boston Scientific, sold 9,689 shares on 2025-01-03 at $89.86, reducing his holdings by 4.1% to 223,921 shares with a total transaction value of $870,636.10. Reviewing his prior transaction history at BSX shows three earlier open-market sales (2024-05-23, 2024-05-22, 2024-02-20), none of which were well-timed at the 90-day mark—the stock rose after each sale, with 90-day returns of +4.9%, +3.4%, and +14.4% respectively. The current price of $90.69 sits near the 52-week high of $91.50 (-0.9%), suggesting the sale occurred near elevated valuation levels. This transaction represents discretionary open-market activity rather than a scheduled plan, and the consistent pattern of selling into strength at BSX (with subsequent positive 90-day returns) warrants observation of how the stock performs in the coming quarter.